Tom Tan-To Cheung1, Philip Chong-Hei Kwok2, Stephen Chan3, Chin-Cheung Cheung4, Ann-Shing Lee5, Victor Lee6, Hoi-Ching Cheng7, Nam-Hung Chia8, Charing C N Chong9, Tak-Wing Lai10, Ada L Y Law11, Mai-Yee Luk6, Chi Chung Tong6, Thomas C C Yau12. 1. Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. 2. Department of Radiology and Imaging, Queen Elizabeth Hospital, Hong Kong, China. 3. Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. 4. Department of Surgery, Tuen Mun Hospital, Hong Kong, China. 5. Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China. 6. Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. 7. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China. 8. Department of Surgery, Queen Elizabeth Hospital, Hong Kong, China. 9. Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. 10. Department of Surgery, Princess Margaret Hospital, Hong Kong, China. 11. Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China. 12. Department of Medicine and Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence. SUMMARY: In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC. These statements are based on the latest evidence and give detailed guidance on how to deploy these modalities, in particular for cases of HCC which are not suited to surgical resection. KEY MESSAGES: These statements give detailed information on how to decide if a patient is a candidate for resection, methods to improve candidacy for resection, and guidance for use of various nonsurgical interventions to manage patients ineligible for resection.
BACKGROUND: Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence. SUMMARY: In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC. These statements are based on the latest evidence and give detailed guidance on how to deploy these modalities, in particular for cases of HCC which are not suited to surgical resection. KEY MESSAGES: These statements give detailed information on how to decide if a patient is a candidate for resection, methods to improve candidacy for resection, and guidance for use of various nonsurgical interventions to manage patients ineligible for resection.
Entities:
Keywords:
Consensus; Hepatocellular carcinoma; Hong Kong; Unresectable HCC
Authors: Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz Journal: JAMA Date: 2010-11-17 Impact factor: 56.272
Authors: Tan To Cheung; Sheung Tat Fan; See Ching Chan; Kenneth S H Chok; Ferdinand S K Chu; Caroline R Jenkins; Regina C L Lo; James Y Y Fung; Albert C Y Chan; William W Sharr; Simon H Y Tsang; Wing Chiu Dai; Ronnie T P Poon; Chung Mau Lo Journal: World J Gastroenterol Date: 2013-05-28 Impact factor: 5.742
Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Aizea Morales-Kastresana; Miguel F Sanmamed; Inmaculada Rodriguez; Asis Palazon; Ivan Martinez-Forero; Sara Labiano; Sandra Hervas-Stubbs; Bruno Sangro; Carmen Ochoa; Ana Rouzaut; Arantza Azpilikueta; Elixabet Bolaños; Maria Jure-Kunkel; Ines Gütgemann; Ignacio Melero Journal: Clin Cancer Res Date: 2013-09-12 Impact factor: 12.531
Authors: G K Glantzounis; E Tokidis; S-P Basourakos; E E Ntzani; G D Lianos; G Pentheroudakis Journal: Eur J Surg Oncol Date: 2016-06-01 Impact factor: 4.424
Authors: Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni Journal: Cardiovasc Intervent Radiol Date: 2009-11-12 Impact factor: 2.740
Authors: Lei Chen; Xiaopeng Guo; Shi Chen; Yanqiao Ren; Tao Sun; Fan Yang; Chuansheng Zheng Journal: Am J Transl Res Date: 2021-01-15 Impact factor: 4.060